Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016055028) THERAPEUTIC COMPOUNDS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/055028 International Application No.: PCT/CN2015/091614
Publication Date: 14.04.2016 International Filing Date: 10.10.2015
IPC:
C07D 223/16 (2006.01) ,C07D 243/12 (2006.01) ,C07D 267/14 (2006.01) ,C07D 281/10 (2006.01) ,A61K 31/551 (2006.01) ,A61K 31/553 (2006.01) ,A61K 31/554 (2006.01) ,A61P 29/00 (2006.01) ,A61P 37/00 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
223
Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
14
condensed with carbocyclic rings or ring systems
16
Benzazepines; Hydrogenated benzazepines
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
243
Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
06
having the nitrogen atoms in positions 1 and 4
10
condensed with carbocyclic rings or ring systems
12
1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
267
Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
02
Seven-membered rings
08
having the hetero atoms in positions 1 and 4
12
condensed with carbocyclic rings or ring systems
14
condensed with one six-membered ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
281
Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
02
Seven-membered rings
04
having the hetero atoms in positions 1 and 4
08
condensed with carbocyclic rings or ring systems
10
condensed with one six-membered ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
553
having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
554
having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
ROMERO, F. Anthony [US/US]; US (MN)
MAGNUSON, Steven R. [US/US]; US (MN)
PASTOR, Richard [US/US]; US (MN)
TSUI, Vickie Hsiao-Wei [US/US]; US (MN)
MURRAY, Jeremy [US/US]; US (MN)
CRAWFORD, Terry [US/US]; US (MN)
BURDICK, Daniel J. [US/US]; US (MN)
ALBRECHT, Brian K. [US/US]; US (MN)
COTE, Alexandre [CA/US]; US (MN)
TAYLOR, Alexander M. [US/US]; US (MN)
NASVESCHUK, Christopher G. [US/US]; US (MN)
LEBLANC, Yves [CA/CA]; CA (MN)
HEWITT, Michael Charles [US/US]; US (MN)
LAI, Kwong Wah [CN/CN]; CN (MN)
CHEN, Kevin [US/CN]; CN (MN)
GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco California 94080, US
CONSTELLATION PHARMACEUTICALS, INC. [US/US]; 215 First Street, Suite 200 Cambridge Massachusetts 02142, US
Inventors:
ROMERO, F. Anthony; US
MAGNUSON, Steven R.; US
PASTOR, Richard; US
TSUI, Vickie Hsiao-Wei; US
MURRAY, Jeremy; US
CRAWFORD, Terry; US
BURDICK, Daniel J.; US
ALBRECHT, Brian K.; US
COTE, Alexandre; US
TAYLOR, Alexander M.; US
NASVESCHUK, Christopher G.; US
LEBLANC, Yves; CA
HEWITT, Michael Charles; US
LAI, Kwong Wah; CN
CHEN, Kevin; CN
Agent:
WU, FENG & ZHANG; Sinosteel Plaza, 21st Floor A/D 8 Haidian st., Haidian Beijing 100080, CN
Priority Data:
PCT/CN2014/08831510.10.2014CN
Title (EN) THERAPEUTIC COMPOUNDS AND USES THEREOF
(FR) COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
Abstract:
(EN) The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
(FR) Cette invention concerne des composés de formule (I): et leurs sels, dans la formule, A ayant l'une quelconque des valeurs définies dans la description, ainsi que des compositions et leurs utilisations. Les composés sont utiles en tant qu'inhibiteurs de CBP et/ou EP300. L'invention porte également sur des compositions pharmaceutiques comprenant un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, et des procédés d'utilisation de tels composés et sels dans le traitement de divers troubles médiés par CBP et/ou EP300.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)